Hyperfractionated irradiation and concurrent cisplatin in brain stem tumors: A pediatric oncology group pilot study (9139)

R. P. Kadota; L. R. Mandell; J. Fontanesi; E. H. Kovnar; J. Krischer; L. E. Kun; H. S. Friedman

doi:10.1159/000120794

Hyperfractionated irradiation and concurrent cisplatin in brain stem tumors: A pediatric oncology group pilot study (9139)

R. P. Kadota, L. R. Mandell, J. Fontanesi, E. H. Kovnar, J. Krischer, L. E. Kun, H. S. Friedman

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

A phase I Pediatric Oncology Group Study was performed combining 7, 020 cGy hyperfractionated irradiation (117 cGy twice daily separated by 6 h) with increasing concurrent doses of cisplatin given with the intent of radiosensitization as treatment for children with newly diagnosed brain stem tumors. Cisplatin was infused over 120 h on weeks 1, 3, and 5 during a 6-week radiotherapy course. The following cisplatin dose levels were studied: (1) 50 mg/m²/120 h, (2) 75 mg/m²/120 h and (3) 100 mg/m²/120 h. Sixteen of 17 children completed therapy. One child expired after 2 days of treatment secondary to massive intratumoral hemorrhage. At cisplatin dose level 3 (100 mg/m²/120 h), grade 2-4 myelosuppression was encountered in 3 of 5 evaluable patients. Otherwise, no other excessive toxicities, including renal and ototoxicity, were noted.

Original language	English (US)
Pages (from-to)	221-225
Number of pages	5
Journal	Pediatric Neurosurgery
Volume	20
Issue number	4
DOIs	https://doi.org/10.1159/000120794
State	Published - 1994

Keywords

Brain neoplasms
Brain stem
Cisplatin
Radiotherapy

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Surgery
Clinical Neurology

Access to Document

10.1159/000120794

Cite this

@article{1191539b2c8547fcb3bf5c48f4722228,

title = "Hyperfractionated irradiation and concurrent cisplatin in brain stem tumors: A pediatric oncology group pilot study (9139)",

abstract = "A phase I Pediatric Oncology Group Study was performed combining 7, 020 cGy hyperfractionated irradiation (117 cGy twice daily separated by 6 h) with increasing concurrent doses of cisplatin given with the intent of radiosensitization as treatment for children with newly diagnosed brain stem tumors. Cisplatin was infused over 120 h on weeks 1, 3, and 5 during a 6-week radiotherapy course. The following cisplatin dose levels were studied: (1) 50 mg/m2/120 h, (2) 75 mg/m2/120 h and (3) 100 mg/m2/120 h. Sixteen of 17 children completed therapy. One child expired after 2 days of treatment secondary to massive intratumoral hemorrhage. At cisplatin dose level 3 (100 mg/m2/120 h), grade 2-4 myelosuppression was encountered in 3 of 5 evaluable patients. Otherwise, no other excessive toxicities, including renal and ototoxicity, were noted.",

keywords = "Brain neoplasms, Brain stem, Cisplatin, Radiotherapy",

author = "Kadota, {R. P.} and Mandell, {L. R.} and J. Fontanesi and Kovnar, {E. H.} and J. Krischer and Kun, {L. E.} and Friedman, {H. S.}",

year = "1994",

doi = "10.1159/000120794",

language = "English (US)",

volume = "20",

pages = "221--225",

journal = "Pediatric Neurosurgery",

issn = "1016-2291",

publisher = "S. Karger AG",

number = "4",

}

TY - JOUR

T1 - Hyperfractionated irradiation and concurrent cisplatin in brain stem tumors

T2 - A pediatric oncology group pilot study (9139)

AU - Kadota, R. P.

AU - Mandell, L. R.

AU - Fontanesi, J.

AU - Kovnar, E. H.

AU - Krischer, J.

AU - Kun, L. E.

AU - Friedman, H. S.

PY - 1994

Y1 - 1994

N2 - A phase I Pediatric Oncology Group Study was performed combining 7, 020 cGy hyperfractionated irradiation (117 cGy twice daily separated by 6 h) with increasing concurrent doses of cisplatin given with the intent of radiosensitization as treatment for children with newly diagnosed brain stem tumors. Cisplatin was infused over 120 h on weeks 1, 3, and 5 during a 6-week radiotherapy course. The following cisplatin dose levels were studied: (1) 50 mg/m2/120 h, (2) 75 mg/m2/120 h and (3) 100 mg/m2/120 h. Sixteen of 17 children completed therapy. One child expired after 2 days of treatment secondary to massive intratumoral hemorrhage. At cisplatin dose level 3 (100 mg/m2/120 h), grade 2-4 myelosuppression was encountered in 3 of 5 evaluable patients. Otherwise, no other excessive toxicities, including renal and ototoxicity, were noted.

AB - A phase I Pediatric Oncology Group Study was performed combining 7, 020 cGy hyperfractionated irradiation (117 cGy twice daily separated by 6 h) with increasing concurrent doses of cisplatin given with the intent of radiosensitization as treatment for children with newly diagnosed brain stem tumors. Cisplatin was infused over 120 h on weeks 1, 3, and 5 during a 6-week radiotherapy course. The following cisplatin dose levels were studied: (1) 50 mg/m2/120 h, (2) 75 mg/m2/120 h and (3) 100 mg/m2/120 h. Sixteen of 17 children completed therapy. One child expired after 2 days of treatment secondary to massive intratumoral hemorrhage. At cisplatin dose level 3 (100 mg/m2/120 h), grade 2-4 myelosuppression was encountered in 3 of 5 evaluable patients. Otherwise, no other excessive toxicities, including renal and ototoxicity, were noted.

KW - Brain neoplasms

KW - Brain stem

KW - Cisplatin

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=0028308824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028308824&partnerID=8YFLogxK

U2 - 10.1159/000120794

DO - 10.1159/000120794

M3 - Article

C2 - 8043459

AN - SCOPUS:0028308824

SN - 1016-2291

VL - 20

SP - 221

EP - 225

JO - Pediatric Neurosurgery

JF - Pediatric Neurosurgery

IS - 4

ER -

Hyperfractionated irradiation and concurrent cisplatin in brain stem tumors: A pediatric oncology group pilot study (9139)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this